Targeting bladder disease where it matters


TARIS Biomedical® is a unique, therapeutically focused urology company developing powerful new treatments for millions of patients suffering from difficult-to-treat bladder diseases. TARIS is advancing therapies for debilitating conditions, including bladder cancer and overactive bladder, enabled by continuous local dosing where it is needed.


Year Invested: 2011
Location: Lexington, Mass.
Visit: www.tarisbiomedical.com

Recent News

November 9, 2018
TARIS Announces Late-Breaking Poster on the Natural History of Muscle-Invasive Bladder Cancer Patients Not Receiving Potentially Curative Therapy

August 28, 2018
TARIS Announces Positive Topline Data for TAR-302 in Patients with Idiopathic Overactive Bladder

April 16, 2018
TARISĀ® Presents Data Demonstrating Significant Local and Systemic Immune Modulation Following Continuous Low-Dose Bladder Delivery of Gemcitabine

Read More News

Associated Team Members

Cary Pfeffer, M.D.
Partner